DelveInsight’s “Polycythemia Vera (PV)- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the PV market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Polycythemia Vera market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Key Facts from the Polycythemia Vera market report
Approximately 92,876 cases of PV were calculated for patients with JAK2 V617F, thereby accounting for the highest number of cases with gene mutation with ~97% of total cases with JAK2 mutation in the United States.
According to DelveInsight’s analysis, it has been observed that is most prevalent in the age group of >75+ years.
According to DelveInsight’s analysis in 2020, among European 5 countries Germany accounted for 24,630 total prevalent population of Polycythemia Vera, followed by France the United Kingdom, then Italy, and at last Spain accounted for 12,771, the lowest total prevalent population. Japan accounted for 32,460 total prevalent population of PV.
In 2020, in the US, 22,641 patients were in the low-risk category, and 77,098 patients were in the high-risk category.
Polycythemia Vera Overview
Polycythemia Vera is a condition characterized by an increased number of red blood cells in the bloodstream (erythrocytosis) and affected people may also have excess white blood cells and platelets. Most cases are not inherited and are acquired during a person’s lifetime.
Polycythemia vera is also known as primary polycythemia. A mutation, or change, in the body’s JAK2 gene, is the main cause of PV. The JAK2 gene makes a protein that helps the body produce blood cells. Common symptoms of polycythemia are headaches, blurred vision, red skin (particularly in the face), hands and feet tiredness, high blood pressure, dizziness, discomfort in the abdomen, confusion, bleeding problems (nosebleeds, and bruising), gout (which can cause joint pain), stiffness and swelling, and itchy skin (especially after a bath or shower).
Polycythemia Vera Epidemiology Insights:
According to NORD (n.d.), Polycythemia vera is a rare, chronic disorder involving the overproduction of blood cells in the bone marrow (myeloproliferation). PV affects slightly more men than women. The disorder is estimated to affect approximately 44 to 57 per 100,000 people in the US. It occurs most often in individuals more than 60 years old but can affect individuals of any age. It is extremely rare in individuals under 20.
According to DelveInsight, the total prevalent population of polycythemia vera (PV) in the 7MM was found to be 296,000 in 2020.
In 2020, among 7MM countries, most of the prevalent cases of PV were found in the United States accounting for 166,230.
Among the European 5 countries, Germany had the highest symptomatic prevalent population of PV with 14,778 cases, followed by France and the United Kingdom, in 2020. On the other hand, Spain had the lowest symptomatic prevalent population of 7,663 in 2020. Besides, Japan had 19,476 symptomatic prevalent cases of PV in 2020.
Polycythemia Vera Epidemiology Segmentation
Polycythemia Vera prevalent cases
Polycythemia Vera prevelant cases based on gene mutation
Polycythemia Vera prevelant cases based on symptoms
Polycythemia Vera prevelant cases based on risk factors
Polycythemia Vera Market Outlook
Patients with Polycythemia Vera, a myeloproliferative neoplasm characterized by an elevated red blood cell mass, are at high risk of vascular and thrombotic complications and have reduced quality of life due to a substantial symptom burden that includes pruritus, fatigue, constitutional symptoms, microvascular disturbances, and bleeding. Conventional therapeutic options aim at reducing vascular and thrombotic risk, with low-dose aspirin and phlebotomy as first-line recommendations for patients at low risk of thrombotic events and cytoreductive therapy (usually hydroxyurea or interferon alpha) recommended for high-risk patients.
Cytoreductive therapies have been used in older patients and those with a history of thrombosis to achieve these goals. Hydroxyurea (HU) remains the first-line cytoreductive choice; however, up to one in four patients treated with HU over time will develop resistance or intolerance to HU and go for the second-line therapy. More importantly, patients who fail HU have a 5.6-fold increase in mortality and a 6.8-fold increased risk of transformation to myelofibrosis or AML; therefore, alternative therapies are needed for these patients.
Interferon-α has been used in PV and has shown significant activity in achieving hematologic responses and decreasing the JAK2 V617F mutation allele burden. JAK inhibition has also been investigated and recently garnered regulatory approval for this indication.
Learn more by requesting for sample @ Polycythemia Vera Market Trends
Polycythemia Vera Key Companies
And many more
Polycythemia Vera Therapies
Table of Contents
Executive Summary of Polycythemia Vera
Disease Background and Overview
Epidemiology and patient population
Polycythemia Vera Emerging Therapies
Polycythemia Vera Market Outlook
Market Access and Reimbursement of Therapies
Polycythemia Vera Report Methodology
Click here to read more about Polycythemia Vera Market Trends
Media ContactCompany Name: DelveInsight Business ResearchContact Person: Gaurav BoraEmail: Send EmailPhone: 8774225362Address:27 Drydock Ave S. Jones Blvd #2432City: BostonState: MACountry: United StatesWebsite: https://www.delveinsight.com/